Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 198 participants.
Also called NCT06041529
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 198 participants
- Sponsor
- Registry
-
NCT06041529
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06041529. Randomized; no masking; primary purpose treatment. Start 2023-10-18 (actual); primary completion 2026-02-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
- Intervention (Drug)
- Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
- Lead sponsor
- Yuhan Corporation
Record details
- Record id
cardio:ct-nct06041529- Content hash
c0d0f47061eefa964800a0cb692b1ed56f1aeaf65b115e38adcccc4254eea4d6